Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...
Starting in September, the UK’s new RSV vaccine program will offer protection across all age groups — find out what this ...
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...
Vicebio has recently initiated a Phase I clinical trial with VXB-241, its bivalent vaccine targeting both RSV and hMPV viruses that cause a significant burden of disease in elderly patients and those ...
KOAT Albuquerque on MSN12d
New guidelines for who should take RSV vaccineIt's been more than a year since the Food and Drug Administration approved the first vaccine to treat RSV. Since then, newly ...
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...
October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
The Respiratory Syncytial Virus (RSV) vaccine will be rolled out to some older islanders as well as pregnant women. | ITV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback